BR112019015832A2 - Método de tratamento de zumbido, método de tratamento de perda auditiva neurossensorial aguda, e método de tratamento da doença de ménière - Google Patents

Método de tratamento de zumbido, método de tratamento de perda auditiva neurossensorial aguda, e método de tratamento da doença de ménière Download PDF

Info

Publication number
BR112019015832A2
BR112019015832A2 BR112019015832-4A BR112019015832A BR112019015832A2 BR 112019015832 A2 BR112019015832 A2 BR 112019015832A2 BR 112019015832 A BR112019015832 A BR 112019015832A BR 112019015832 A2 BR112019015832 A2 BR 112019015832A2
Authority
BR
Brazil
Prior art keywords
gaboxadol
patient
pharmaceutically acceptable
acceptable salt
hours
Prior art date
Application number
BR112019015832-4A
Other languages
English (en)
Portuguese (pt)
Inventor
During Matthew
Original Assignee
Ovid Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc. filed Critical Ovid Therapeutics Inc.
Publication of BR112019015832A2 publication Critical patent/BR112019015832A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112019015832-4A 2017-02-03 2018-02-02 Método de tratamento de zumbido, método de tratamento de perda auditiva neurossensorial aguda, e método de tratamento da doença de ménière BR112019015832A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762454280P 2017-02-03 2017-02-03
US62/454,280 2017-02-03
US201762530528P 2017-07-10 2017-07-10
US62/530,528 2017-07-10
US201762536669P 2017-07-25 2017-07-25
US62/536,669 2017-07-25
PCT/US2018/016602 WO2018144827A1 (en) 2017-02-03 2018-02-02 Use of gaboxadol in the treatment of tinnitus

Publications (1)

Publication Number Publication Date
BR112019015832A2 true BR112019015832A2 (pt) 2020-03-31

Family

ID=63038963

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019015832-4A BR112019015832A2 (pt) 2017-02-03 2018-02-02 Método de tratamento de zumbido, método de tratamento de perda auditiva neurossensorial aguda, e método de tratamento da doença de ménière

Country Status (17)

Country Link
US (3) US10071083B2 (cg-RX-API-DMAC7.html)
EP (1) EP3576738B1 (cg-RX-API-DMAC7.html)
JP (3) JP2020505432A (cg-RX-API-DMAC7.html)
KR (1) KR20190112046A (cg-RX-API-DMAC7.html)
CN (1) CN110402140A (cg-RX-API-DMAC7.html)
AU (1) AU2018215363A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019015832A2 (cg-RX-API-DMAC7.html)
CA (1) CA3051586A1 (cg-RX-API-DMAC7.html)
DK (1) DK3576738T3 (cg-RX-API-DMAC7.html)
ES (1) ES2930899T3 (cg-RX-API-DMAC7.html)
HU (1) HUE060609T2 (cg-RX-API-DMAC7.html)
IL (1) IL268210A (cg-RX-API-DMAC7.html)
MX (1) MX393900B (cg-RX-API-DMAC7.html)
PE (1) PE20191407A1 (cg-RX-API-DMAC7.html)
PL (1) PL3576738T3 (cg-RX-API-DMAC7.html)
PT (1) PT3576738T (cg-RX-API-DMAC7.html)
WO (1) WO2018144827A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108024997A (zh) 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
EP3833351A4 (en) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
KR20210110585A (ko) 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
MX2021007224A (es) * 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
EP4299059A1 (en) 2022-07-01 2024-01-03 Labelic Analysis, S.L. Composition for the treatment of tinnitus

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20070032553A1 (en) * 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
DE102005004343A1 (de) 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
US20080262029A1 (en) * 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DK2083811T3 (en) 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
DE102007063210A1 (de) 2007-12-20 2009-06-25 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung von Phantomphänomenen
EP2254577A1 (en) * 2007-12-26 2010-12-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
CN107050456B (zh) 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
US20130309306A1 (en) 2010-12-01 2013-11-21 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US20140371210A1 (en) 2011-10-13 2014-12-18 Jaleva Pharmaceuticals, Llc Methods and compositions for rapid transbuccal delivery of active agents
US20150313915A1 (en) 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
US20150313913A1 (en) 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
EP3795156A1 (en) 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Pharmaceutical composition for treating angelman syndrome
EP3154979B1 (en) 2014-06-12 2018-03-07 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
CN108024997A (zh) 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
AU2016304737B2 (en) 2015-08-11 2021-03-11 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
KR20210110585A (ko) * 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌

Also Published As

Publication number Publication date
JP2020505432A (ja) 2020-02-20
US20180344709A1 (en) 2018-12-06
AU2018215363A1 (en) 2019-08-15
MX2019009190A (es) 2019-09-26
PL3576738T3 (pl) 2023-02-06
EP3576738B1 (en) 2022-10-12
MX393900B (es) 2025-03-24
EP3576738A4 (en) 2021-02-17
ES2930899T3 (es) 2022-12-22
US20190111033A1 (en) 2019-04-18
CA3051586A1 (en) 2018-08-09
US20180221355A1 (en) 2018-08-09
US10188635B2 (en) 2019-01-29
PE20191407A1 (es) 2019-10-04
HUE060609T2 (hu) 2023-04-28
DK3576738T3 (da) 2022-11-28
KR20190112046A (ko) 2019-10-02
WO2018144827A1 (en) 2018-08-09
IL268210A (en) 2019-09-26
US10071083B2 (en) 2018-09-11
PT3576738T (pt) 2022-11-30
JP2024178317A (ja) 2024-12-24
EP3576738A1 (en) 2019-12-11
CN110402140A (zh) 2019-11-01
JP2023011630A (ja) 2023-01-24

Similar Documents

Publication Publication Date Title
US10071083B2 (en) Use of gaboxadol in the treatment of tinnitus
Kupfer Pathophysiology and management of insomnia during depression
US20160166543A1 (en) Stable combination oral liquid formulation of melatonin and an antihistaminic agent
ES2824552T3 (es) Método de tratamiento con tradipitant
AU2019216742B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
JP2021080276A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
RU2008150622A (ru) Лечение агонистом мелатонина
US20100204205A1 (en) Tolerability of mirtazapine and a second active agent by using them in combination
US11744833B2 (en) Pharmaceutical compositions and methods for treatment of insomnia
WO2023158424A1 (en) Novel pharmaceutical compositions and methods for treatment of insomnia
Im et al. Management of sleep disorders in stroke
CN116134048A (zh) 用于治疗神经精神障碍的组合物和方法
Conroy et al. Insomnia in patients with addictions: A safer way to break the cycle
US11771671B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
HK40015478A (en) Use of gaboxadol in the treatment of tinnitus
US20260108529A1 (en) Fused amino pyrimidine compounds for treatment of tinnitus, acute sensorineural hearing loss, age-related hearing loss, and meniere's disease
JP2022540917A (ja) 治療的処置のためのガボキサドール含有医薬製剤
Cyrus Review of Pharmacologic Sleep Agents for Critically III
Neubauer et al. Pharmacological Management of Insomnia
Lippmann et al. Problems with sleep: What should the doctor do?
Bunka Chronic Insomnia in Older Adults
Montagna et al. Treatment of Sleep-Related Movement Disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2812 DE 26/11/2024.